Andrew McGarry

1.3k total citations
23 papers, 220 citations indexed

About

Andrew McGarry is a scholar working on Cellular and Molecular Neuroscience, Neurology and Molecular Biology. According to data from OpenAlex, Andrew McGarry has authored 23 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cellular and Molecular Neuroscience, 14 papers in Neurology and 9 papers in Molecular Biology. Recurrent topics in Andrew McGarry's work include Genetic Neurodegenerative Diseases (12 papers), Neurological disorders and treatments (11 papers) and Parkinson's Disease Mechanisms and Treatments (5 papers). Andrew McGarry is often cited by papers focused on Genetic Neurodegenerative Diseases (12 papers), Neurological disorders and treatments (11 papers) and Parkinson's Disease Mechanisms and Treatments (5 papers). Andrew McGarry collaborates with scholars based in United States, Canada and United Kingdom. Andrew McGarry's co-authors include Karl Kieburtz, Charles S. Venuto, Qing Ma, C. Warren Olanow, Michael R. Hayden, Michal Geva, Kevin Biglan, Karl Kieburtz, Igor D. Grachev and Peggy Auinger and has published in prestigious journals such as Neurology, Scientific Reports and Movement Disorders.

In The Last Decade

Andrew McGarry

21 papers receiving 215 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew McGarry United States 9 161 121 113 22 15 23 220
Alex Medina Canada 4 107 0.7× 67 0.6× 78 0.7× 18 0.8× 13 0.9× 10 185
Keith Malarick United States 4 122 0.8× 148 1.2× 76 0.7× 48 2.2× 9 0.6× 4 221
Amy Smith-Dijak Canada 8 248 1.5× 185 1.5× 120 1.1× 17 0.8× 5 0.3× 9 295
Cristina Cariulo Italy 9 169 1.0× 162 1.3× 86 0.8× 29 1.3× 11 0.7× 11 254
Nathalie Nilsson Sweden 5 81 0.5× 66 0.5× 51 0.5× 37 1.7× 10 0.7× 8 152
Justo García de Yébenes Spain 3 129 0.8× 95 0.8× 97 0.9× 9 0.4× 6 0.4× 4 169
Reem A. Alkhater Canada 6 90 0.6× 68 0.6× 64 0.6× 19 0.9× 19 1.3× 8 207
Mireille Meunier France 6 90 0.6× 61 0.5× 78 0.7× 9 0.4× 9 0.6× 9 159
Audrey Olivier France 4 134 0.8× 77 0.6× 87 0.8× 7 0.3× 17 1.1× 6 161
Fernando Morales Costa Rica 10 335 2.1× 352 2.9× 97 0.9× 12 0.5× 6 0.4× 26 421

Countries citing papers authored by Andrew McGarry

Since Specialization
Citations

This map shows the geographic impact of Andrew McGarry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew McGarry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew McGarry more than expected).

Fields of papers citing papers by Andrew McGarry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew McGarry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew McGarry. The network helps show where Andrew McGarry may publish in the future.

Co-authorship network of co-authors of Andrew McGarry

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew McGarry. A scholar is included among the top collaborators of Andrew McGarry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew McGarry. Andrew McGarry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McGarry, Andrew & Ruin Moaddel. (2025). A Pilot Proteomic Analysis of Huntington’s Disease by Functional Capacity. Brain Sciences. 15(1). 76–76. 1 indexed citations
2.
McGarry, Andrew, Jackson Liscombe, Michael Neumann, et al.. (2025). Much More Than the Malady: The Promise of a Web-Based Digital Platform Incorporating Self-Report for Research and Clinical Care in Mild Cognitive Impairment. PubMed. 3(2). 100224–100224. 1 indexed citations
3.
Rissardo, Jamir Pitton, et al.. (2025). Neurobiology of Dystonia: Review of Genetics, Animal Models, and Neuroimaging. Brain Sciences. 15(7). 767–767.
4.
Olanow, C. Warren, Deborah McIntyre, Michele Matarazzo, et al.. (2024). Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study. Movement Disorders. 39(6). 945–954. 5 indexed citations
5.
Rissardo, Jamir Pitton, Andrew McGarry, Thomas N. Ferraro, et al.. (2024). Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia. Brain Sciences. 14(12). 1163–1163. 2 indexed citations
6.
McGarry, Andrew, Krystal Hunter, John Gaughan, et al.. (2024). An exploratory metabolomic comparison of participants with fast or absent functional progression from 2CARE, a randomized, double-blind clinical trial in Huntington’s disease. Scientific Reports. 14(1). 1101–1101. 4 indexed citations
7.
Werner, Milton H., C. Warren Olanow, Andrew McGarry, et al.. (2024). A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease. Journal of Parkinson s Disease. 14(2). 325–334. 4 indexed citations
8.
McGarry, Andrew & Karl Kieburtz. (2023). Adaptive clinical trials and master protocols. Handbook of clinical neurology. 193. 313–323.
9.
10.
McGarry, Andrew, et al.. (2022). Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington Disease. Neurology Clinical Practice. 12(2). 131–138. 2 indexed citations
11.
Reilmann, Ralf, Anne Rosser, Sandra K. Kostyk, et al.. (2021). F41 The proof-hd phase 3 study: pridopidine’s outcome on function in huntington disease (PROOF). A36.1–A36. 1 indexed citations
12.
McGarry, Andrew, John Gaughan, Cory Hackmyer, et al.. (2021). Author Correction: Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington’s disease for participants of varying functional disability: a pilot study. Scientific Reports. 11(1). 9947–9947. 1 indexed citations
13.
Kieburtz, Karl, Russell Katz, Andrew McGarry, & C. Warren Olanow. (2020). A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic. Movement Disorders. 36(1). 59–63. 15 indexed citations
14.
McGarry, Andrew, John Gaughan, Cory Hackmyer, et al.. (2020). Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington’s disease for participants of varying functional disability: a pilot study. Scientific Reports. 10(1). 20490–20490. 24 indexed citations
15.
McGarry, Andrew, Mika Leinonen, Karl Kieburtz, et al.. (2020). Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. Journal of Huntington s Disease. 9(4). 371–380. 24 indexed citations
16.
McGarry, Andrew & Kevin Biglan. (2017). Preclinical motor manifestations of Huntington disease. Handbook of clinical neurology. 144. 93–98. 9 indexed citations
17.
Kieburtz, Karl, G. Bernhard Landwehrmeyer, Ralf Reilmann, et al.. (2017). Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (P2.005). Neurology. 88(16_supplement). 10 indexed citations
18.
McGarry, Andrew, Karl Kieburtz, Victor Abler, et al.. (2017). Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington’s Disease. Journal of Huntington s Disease. 6(3). 189–199. 13 indexed citations
19.
Venuto, Charles S., Andrew McGarry, Qing Ma, & Karl Kieburtz. (2011). Pharmacologic approaches to the treatment of Huntington's disease. Movement Disorders. 27(1). 31–41. 64 indexed citations
20.
Goodman, LaVonne, Louise Vetter, Charles S. Venuto, et al.. (2011). Advocacy Recruiting for Huntington’s Disease Clinical Trials. PLoS Currents. 3. RRN1230–RRN1230. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alex Medina Breakdown of academic impact, for papers by Keith Malarick Breakdown of academic impact, for papers by Amy Smith-Dijak Breakdown of academic impact, for papers by Cristina Cariulo Breakdown of academic impact, for papers by Nathalie Nilsson Breakdown of academic impact, for papers by Justo García de Yébenes Breakdown of academic impact, for papers by Reem A. Alkhater Breakdown of academic impact, for papers by Mireille Meunier Breakdown of academic impact, for papers by Audrey Olivier Breakdown of academic impact, for papers by Fernando Morales
Rankless by CCL
2026